Anavex Life Sciences Corporation

AVXL

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
May 13, 2024

Days Left:
-144

calendar

Allegations

The complaint alleges that on December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. An analyst questioned the Company’s claim noting “there are several key factors that point us to believe the data is provocative, but not yet compelling, given the choice of statistical analyses and other trial design/conduct ‘complexifiers’.” Additionally, a biotech journalist commented on AVXL’s findings stating “[w]hat sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials…Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.” Following this news, AVXL’s stock price fell by $2.47 per share, or approximately 20% to close at $9.58. Further on January 3, 2024, AVXL announced that results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73 in pediatric patients with Rett syndrome failed to show statistical significance towards its primary endpoints. Biotech analysts commented that “the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results.” Following this news, AVXL’s stock price fell by $3.26 per share, or approximately 35%.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Anavex Life Sciences purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Anavex Life Sciences during the relevant time frame, you have until May 13, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Find More Cases

Ticker Symbol Company Name Deadline
XPEL XPEL, Inc. October 07, 2024 View
F Ford Motor Company October 07, 2024 View
LULU Lululemon Athletica Inc. October 07, 2024 View
XPEL XPEL Technologies Corp. October 07, 2024 View
MRNA Moderna, Inc. October 08, 2024 View
NNE NANO Nuclear Energy Inc. October 08, 2024 View
CXM Sprinklr, Inc. October 15, 2024 View
STLA Stellantis N.V. October 15, 2024 View
SYM Symbotic Inc. October 15, 2024 View
EXTR Extreme Networks, Inc. October 15, 2024 View
PDD PDD Holdings Inc. f/k/a Pinduoduo Inc. October 15, 2024 View
ARDX Ardelyx, Inc. October 15, 2024 View
OFIX Orthofix Medical Inc. October 21, 2024 View
DXCM DexCom, Inc. October 21, 2024 View
SPIR Spire Global, Inc. October 21, 2024 View
STM STMicroelectronics N.V. October 22, 2024 View
DAVA Endava plc October 25, 2024 View
MEI Methode Electronics, Inc. October 25, 2024 View
SAGE Sage Therapeutics, Inc. October 28, 2024 View
VERV Verve Therapeutics, Inc. October 28, 2024 View
SBUX Starbucks Corporation October 28, 2024 View
OM Outset Medical, Inc. October 28, 2024 View
SMCI Super Micro Computer, Inc. October 29, 2024 View
ZI ZoomInfo Technologies Inc. November 04, 2024 View
WBTN WEBTOON Entertainment Inc. November 04, 2024 View
GTLB GitLab Inc. November 04, 2024 View
GTLB GitLab Inc. November 04, 2024 View
AGEN Agenus Inc. November 05, 2024 View
NFE New Fortress Energy Inc. November 18, 2024 View
DPZ Domino's Pizza, Inc. November 19, 2024 View
MGX Metagenomi, Inc. November 25, 2024 View
BMBL Bumble Inc. November 25, 2024 View
LLAP Terran Orbital Corporation November 26, 2024 View
LLAP Terran Orbital Corporation November 26, 2024 View
FNA Paragon 28, Inc. November 29, 2024 View